Shovon Ashraf is a partner in Goodwin's Technology and Life Sciences groups.  Working closely with clients, Mr. Ashraf develops and implements strategies to procure sophisticated worldwide patent estates that protect clients’ current and future business interests.  As a trusted counselor to clients, Mr. Ashraf assists clients to strategically innovate products and processes to be free of third-party patent rights (through freedom to operate (FTO) assessments), and to build patent estates positioned to preclude market competition (through patent landscape assessments (patentability analysis)).  The strategies for innovation and patent estates built by Mr. Ashraf can be primers for clients to leverage as opportunities for collaboration and licensing, or to preclude market competition.

Dr. Ashraf works primarily in the life sciences, with particular focus on immuno-oncology, immunotherapy, therapeutic antibodies and multi-specific binding proteins, cell therapy, gene therapy, vaccines, enzyme replacement therapy, synthetic oligonucleotide therapeutics (e.g., antisense oligonucleotides), probiotics, drug-delivery device, and biomolecule-based drug-delivery systems.

As a member of the Life Sciences Practice at Goodwin, Mr. Ashraf also evaluates competitive landscapes to assess patentability and freedom to operate positions for investors; and collaborates closely with the licensing and corporate teams at Goodwin to advise clients on license agreements and research and collaboration agreements.

Areas of Practice
Domaines D’Expertise





Dr. Ashraf’s representative experience includes patent counseling and IP due diligence relating to the following deals:

  • Represented biotech companies in patent procurement and IP strategy in antibody and immunotherapy space
  • Represented life sciences companies in patent procurement and IP strategy in gene therapy, RNA-based therapeutics, and cellular therapy
  • Assisted Dragonfly Therapeutics in its research and collaboration agreement with Gilead Sciences with an upfront payment of $300 million designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications
  • Assisted Dragonfly Therapeutics in its $475 million exclusive license agreement with Bristol-Myers Squibb for Dragonfly’s IL-12 investigational immunotherapy program
  • Assisted a Google Venture NewCo on IP diligence during early stages of product design and development
  • Assisted QurAlis Corporation in its $42 million Series A financing to develop new therapies for Amyotrophic Lateral Sclerosis (ALS)
  • Assisted Anthos Therapeutics in its exclusive license agreement with Novartis for the development and commercialization of an anti-Factor XI/XIa antibody
  • Assisted Fresenius Medical Care in its strategic global partnership with Humacyte supported by a $150 million equity investment
  • Represented a clinical-stage biopharmaceutical company in their Series A financing
  • Assisted Dragonfly Therapeutics in its exclusive research and collaboration agreement with Bristol-Myers Squibb with an upfront payment of $55 million to develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets
  • Assisted Dragonfly Therapeutics in its strategic collaboration agreement with Merck with the potential to earn Dragonfly up to $695 million in upfront and milestone payments to develop Dragonfly’s TriNKETTM technology platform for a number of solid-tumor programs
  • Assisted Allena Pharmaceuticals in its $75 million initial public offering
  • Assisted Juvenescence Ltd. in its 14.4 million share purchase of AgeX Therapeutics for $43.2 million
  • Assisted ProQR Therapeutics N.V. in their $20 million public offering and concurrent registered direct offering of ordinary shares
  • Advised Cydan II, Inc. on licensing matters
Professional Activities

Dr. Ashraf is a member of the Boston Bar Association.

Professional Experience

Prior to joining Goodwin in 2016, Dr. Ashraf was an associate in the Intellectual Property group at Mintz Levin PC (Boston), and, prior to joining Mintz Levin, Dr. Ashraf was a Technical Specialist at Sterne, Kessler, Goldstein, & Fox (Washington, D.C.).


Dr. Ashraf has been named as a Massachusetts Rising Star by Super Lawyers in each year of 2015-2020.

In The News









J.D., 2013
The George Washington University Law School
M.S., Epidemiology, 2006
Harvard School of Public Health
Ph.D., Cell Biology, 2001
University of Massachusetts Medical School



U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique